# Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

> **NCT01564563** · PHASE2 · TERMINATED · sponsor: **Novo Nordisk A/S** · enrollment: 11 (actual)

## Conditions studied

- Acquired Bleeding Disorder
- Bleeding During/Following Surgery

## Interventions

- **DRUG:** standard therapy
- **DRUG:** placebo
- **DRUG:** activated recombinant human factor VII
- **DRUG:** activated recombinant human factor VII

## Key facts

- **NCT ID:** NCT01564563
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-06-28
- **Primary completion:** 2003-10-27
- **Final completion:** 2003-10-27
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Trial enrollment was prematurely terminated due to excessively slow patient recruitment
- **Last updated:** 2017-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01564563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01564563, "Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01564563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*